Previous Close | 131.62 |
Open | 134.66 |
Bid | 131.95 |
Ask | 133.75 |
Strike | 660.00 |
Expire Date | 2024-09-20 |
Day's Range | 134.66 - 134.66 |
Contract Range | N/A |
Volume | |
Open Interest | 33 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.